From Expert Review of Anti-Infective Therapy

Dengue Fever: Diagnosis and Treatment
Viroj Wiwanitkit Authors and Disclosures

Abstract and Introduction
Abstract

Dengue fever is a common tropical infection. This acute febrile illness can be a deadly infection in cases of severe manifestation, causing dengue hemorrhagic shock. In this brief article, I will summarize and discuss the diagnosis and treatment of this disease. For diagnosis of dengue, most tropical doctors make use of presumptive diagnosis; however, the definite diagnosis should be based on immunodiagnosis or viral study. Focusing on treatment, symptomatic and supportive treatment is the main therapeutic approach. The role of antiviral drugs in the treatment of dengue fever has been limited, but is currently widely studied.
Introduction

Dengue is a significant mosquito-borne infection. An arbovirus named dengue virus is the causative agent. Due to the nature of the mosquito-borne infection, dengue has become a significant public health threat in many developing tropical countries. Dengue had been present throughout tropical regions of the world for more than 50 years.[1] Of several tropical regions, Southeast Asia is accepted as the area with the highest prevalence of this disease. A severe hemorrhagic form of dengue infection has become a leading infectious cause of death for local people in Southeast Asia. Francisco Pinheiro, a former researcher from the Division of Disease Prevention and Control, and the Special Program for Vaccines and Immunization, Pan American Health Organization (DC, USA), said that the highest incidence of dengue could be seen in Southeast Asia, particularly in Vietnam and Thailand, which together account for more than two-thirds of the overall reported cases in Asia.[2] Hence, several groups are now carrying out research and developmen t on dengue infection in this area. At present, due to the efficient mosquito-borne method by which the virus is transported, dengue is not confined within the tropical region, but is sporadically reported from many nontropical countries. It is accepted that it is now a global issue. In South Asia, there have been many reports of dengue epidemiology coming in from India. An increased incidence among the pediatric population in the over populated areas can be seen.[3] Dengue infection has also been reported in nontropical regions of Asia, such as East Asia and China.[4] Luo et al. noted that epidemics of dengue fever are closely related to the situation of neighboring countries, especially those is Southeast Asia. This indicated the possibility of importation of viruses from these countries, with the epidemics usually arising due to immigration of dengue patients from endemic areas.[5] Similarly, dengue infections also already extend to Australia and dengue [6] has been accepted as a significant emerging infection of concern in Australia. Outbreak of dengue infection in North Queensland gave great concern to the local CDC.[7] In Queensland, it is advised that general practitioners report all clinically suspected cases of dengue in any arriving travelers.[8] For Africa, America,[9±11] Europe[12±14] and Africa[15±17] the increase in reported cases of dengue highlights the necessity to prepare to combat this viral disease. Focusing on the natural characteristics of dengue, this acute febrile illness can be deadly in cases of severe manifestation, causing dengue hemorrhagic shock. Patients usually visit the physician on the second or third day after the first appearance of fever, and after self-treatment of the illness by some selfprescribed antipyretic drugs.[18] However, after unsuccessful self-treatment, the patients usually end up visiting the physician with a chief complaint of an unexplained high fever and malaise. In this brief article, I will summarize and discuss the diagnosis and treatment of this disease.

As previously mentioned. The WHO also suggests using the tourniquet test as a vital parameter in the diagnosis of dengue. the pathogenic agent for dengue is an arbovirus namely 'dengue virus'. disturbance of hemostasis is another important pathological process in dengue infection. In the simple form of dengue infection. What is New in Diagnosis of Dengue? Generally. Also.[22. seen after application of the tourniquet test. Natural History & Clinical Manifestation of Dengue Before the diagnosis and treatment.[19] Hence.[34] Cao et al. a petechia is the only sign of infection.32] gastrointestinal and respiratory symptoms can be detected. most dengue infections are classified as simple dengue fever. It is observed that hematocrit progressively increases and platelet count progressively decreases from simple [28] dengue to dengue shock syndrome. Generally. The infection cause vascular s leakage as well as platelet destruction. Due to its nature as a viral infection. malaise and myalgia with a rash developing after 3± 4 days is common.[24±27] Hence. Focusing on the serious form of dengue. high morbidity and mortality can be expected if appropriate treatment is not administered.[29±31] however. dengue virus is transmitted by the mosquito vector. These atypical infections can manifest without fever or clinically serious symptoms.23] the destruction of the platelet in dengue hemorrhagic fever is the result of an immune mimicking process between parts of the dengue virus and the platelet that cause autodestruction of the platelet by IgM. the self limitation of platelet destruction after the acute phase of infection can be seen in the natural history of dengue.[29±31] The fever usually lasts 4±7 days due to the nature of viral infection. the stimulation of lymphocytes results in lymphocytosis with atypical lymphocyte reactions. if severe infection occurs. The cause of thrombocytopenia in dengue is thought to be an immune -related process. Focusing on the pathogenesis of dengue. As an nd arbovirus.[33] However. Aedes aegypti is the main carrier is responsible for approximately two-thirds of the world's dengue. Generally. Most patients experience a complete recovery without complications. the diagnosis in many endemic countries is usually a presumptive diagnosis via clinical evidence of acute febrile illness with decreased platelet count. in severe cases. a number of atypical forms of clinical manifestation can be [29±31] seen. aegypti-to-human contact. a pattern of acute viral infection can be seen. as previously mentioned. natural history and clinical manifestation of dengue should be discussed. lymphotropic phenomenon can be seen. results in thrombocytopenia and bleeding. mentioned that the tourniquet test was a helpful indication of dengue infec tion in [34] diagnosis in highly rural areas in endemic countries. the important bioecological parameters that can promote worldwide transmission of dengue include the nature of the A. The affected patients usually present with high fever (almost all cases[28]) and present a positive tourniquet test. the susceptibility of the mosquito and the method of transmission. The tourniquet test is an important basic screening test for dengue. dengue is classified as a blood infection and the main reaction of the human body to dengue virus can be seen in the circulation. there is no doubt that when dengue virus is carried to a new setting. an incubation period of 5 days ±8 followed by the onset of a high-peak fever. the forms with overt bleeding (dengue hemorrhagic f ver) and e shock (dengue shock syndrome) are classified as dengue with high severity.[27] Concerning the natural history of dengue. Aedes spp. presumably due to increasing hemoconcentration.[20] These factors can vary across different areas and are important determinants to take into account in areas of dengue emergence. An important step in the management of dengue is monitoring severe forms of infection. There are four serotypes of dengue virus that can be seen arou the world. further transmission by local mosquitos can easily occur.Pathogenesis. and [28. The main reason for this practice is the limited . Focusing on epidemiology. headache. the pathogenesis.[21] which.

the application of nanodiagnostictools for [44] diagnosis of tropical diseases is the present focus in tropical medicine. the problem of quality control and standardization of molecular [40. since most patients do not visit the physician during the early stages of the disease. discussed the need to combine IgM antibody detection with the detection of virus or viral RNA using real-time PCR for early diagnosis of dengue.[37.[48] Some patents have recently been granted for such point-of-care tests (such as WO/2009/139725). amplified by PCR. is another important aim in diagnostic test kit development. the interpretation of the test results has to be done carefully. However.[47] Additionally. and the chance of following up with a serological test is commonly lost. Schilling et al. However. False positives may be generated in vitro when using the PCR-based tests.41] based diagnostic test kits for dengue should be considered. suggested that. However. there have been several attempts to develop new nanodiagnostic tools for dengue. however. Also. to date. Of interest. and IgM and IgG ELISA assays are examples of immunological-based tests used for definitive diagnosis of dengue. Most of these reports usually mention its use in the rapid and effective diagnosis of dengue at the very early phase of infection. Hemaglutination inhibition.43] Nanodiagnostic Tools for Dengue Nanodiagnosis is the new challenge in laboratory medicine. It is advisable that further studies should be performed to verify the cost±effectiveness of using PCR-based techniques compared with classical presumptive diagnosis of dengue in real practice. although dengue is considered a problematic emerging infection in .[36] Molecular Diagnostic Tool for Dengue As mentioned earlier. Focusing on the present definitive diagnosis. the use of nanomaterial to enhance the immunological reaction. the microfluidic system for dengue detection that has been reported in the literature[45] can be upgraded into the nanofluidic system by adjustment of the internal electromagnetic system.resources and the fact that there is little change in therapeutic management after receiving a definite diagnosis method. more rapid test for diagnosis of dengue is required. no launched diagnostic test kit has been launched. viral study is rarely performed andthe immunological-based test is more widely used. thereby allowing visibility of the presence of the virus with the naked eye to help ease the diagnostic procedure. Indeed. since it has been shown to be able to detect dengue viruses up to the tenth day after the onset of the symptoms".[40.41. a new. "RTPCR is definitely the most satisfactory test that can be used on these infections.38] De Paula et al.[46] Combining nanotechnology with molecular diagnostic techniques may be the key to success in the development of a new nanofluidic system for dengue virus determination. There have been many reports recently onusing PCR techniques for diagnosis of dengue. However. subsequently. the big problem in implementing these PCR-based techniques for real-life use in endemic areas in developing countries is the cost of the test kits. ne utralization. the immunological based test or viral study can be applied.[35] Also. the trend of using a molecular-based diagnostic tool such as PCR-based test kits has become the new approach for early diagnosis of dengue. since falsely primed cDNAs may be generated during the reverse transcription step and. relating to the timing of serum collection.[42] Specific international control and validation of the currently used test kits is suggested to avoid this problem. Although the immunological based test does not significantly change the management of the infected case. Point-of-care Testing for Dengue Diagnosis A new challenge in point-of-care technology is the development of diagnostic tests that can be applied f r o use against emerging infections.[38] Identification and [39] quantification of distinct dengue virus strains and serotypes in clinical samples (most preferably serum ) [37] can be performed by PCR-based techniques. due to the complex process involved in isolating the virus. it is useful for epidemiological records and disease±control planning. At present.

[50] What is New in Treatment of Dengue? Given that dengue is an infection. The possibility of treatment of dengue via antiviral drugs is still under investigation. persistent vomiting and clinical fluid accumulation). the principles of dengue management are still concordant with those discussed earlier. treatment can be performed using the simple concept of 'getting rid of the pathogen and limiting the complications'..[57] In addition to the antiviral drug. The use of computational biology. A basic follow-up laboratory test should be used to evaluate the hematocrit and platelet count.[53] In modern medicine.[49] There are some commercial products. bioinformatics and high -throughput screening can be helpful for [56±58] searching of new antiviral drug for dengue. the use of supportive and symptomatic treatment is widely used for dengue treatment. abdominal pain. At present. aiming to limit the complications of the infection. glycyrrhizin and 6-azauridine are reported to have cytostatic and inhibitory effects on the dengue virus. For example. however. In phytomedicine. It is noted that a progressive rise in hematocrit with a progressive reduction of platelet count implies a high risk for developing shock. then the rate can be adjusted according to the status of the patient in the following 16 h. This classification system aids earlier detection of complicated cases. The applic ation of fluid therapy has become key in dengue management and this is applied based on the severity of disease. ribavirin. intravenous fluid replacement by either colloids or crystalloids should be considered in order to prevent shock.e. In severe cases of dengue infection. followed by 10 ml/kg/h for 6 h. the new classifications of dengue disease are: dengue without warning signs (i. severe hemorrhage and severe organ impairment). The immunochip produced by Wu et al. there are only a few point-of-care testing products for dengue diagnosis avaliable. The preferable new treatment for dengue would be an antiviral drug.many settings.[52] This monitoring should be done for at least 1 day after the discontinuation of intravenous fluid administration to prevent possible fluid intoxication in the convalescent phase due to fluid redistribution. Parenteral. there have been a lot of attempts to discover one. that have been evaluated for clinical diagnosis. Diagnosis via new molecularbased techniques have become a new hope for early diagnosis.[101] Based on this publication. a specific antiviral drug is not available. dengue with warning signs and severe dengue (i. it is also useful to discuss the new guidelines published by the WHO and the Special Programme for Research and Training in Tropical Diseases. is the best example. Freser and Miertus screened a combinatorial library of peptidomimetic inhibitors of dengue virus NS2B -NS3 protease via the described in silico technique.[51] The basic recommendation for intravenous fluid-replacement therapy is administration of 0. oral fluid replacement is sufficient and there is no need for hospitalization. This technique helps identify and understand the molecular structure of dengue for prediction of binding to the newly developed drug.. In simple dengue.[54] An adenosine analog is another [55] promising drug currently being studied. fluid replacement should be carefully used and must be performed under close observation in a hospital. In general.e.9% normal saline solution at a rate of 20 ml/kg/h in the first 2 h. however. severe plasma leakage. The chemical 'NITD008' is the best example. several sulfated polysaccharides extracted from seaweeds have been studied and high antiviral activity against dengue virus has been observed.[52] Water and electrolyte status should be maintained during treatment to avoid under and over administration of fluid. . either ELISA or rapid strip assay. Conclusion Dengue virus is a currently a problematic global infection. but are still limited due to their costs and standardization. Recent development in dengue diagnosis is the nonstructural one -antigen test or 'NS1 test'.

Recurrence and emergence of infectious diseases in Djibouti city. Am. J. 35. Shah I. Dengue 3 virus transmission in Africa. Chakib SO. 5. Rev. Tardeja PN. Outbreak of dengue in Mumbai and predictive markers for dengue shock syndrome. References 1. 16. 60±65 (1977). HIV. 9. Jou JM. In diagnosis. Phillips DA. 1990±2000. 2. 212±218 (2001). 1693±1704 (2000). Annu. Clin. Hills SL. Vidal J. 286±289 (2003). Vaughn DW. . Marcus U. Dwyer DE. rapidly controlled outbreak of dengue fever in two suburbs in Townsville. Jiang L. NZ J. Cabral JR. Microbes Infect. Global situation of dengue and dengue haemorrhagic fever. Humphreys JL. 2. Pediatr. Malcolm RL. Travel Med. 7. 161±169 (1997). Aust. R. Invited commentary: dengue lessons from Cuba. dengue will still be a prominent viral infection. Current status in the prevention and control of dengue fever in China. 800±803 (2000). Brouqui P et al. 71. Hanna JN. 26.) 111. Med. Public Health 24. Bull. A clinical and epidemiological study in 57 Spanish travelers. Corber SJ. Dengue virus infections in Nigeria: a survey for antibodies in monkeys and humans. 2001. Med. Piispanen JP. Watts DM. 6. Corachan M. and its emergence in the Americas. Dengue: a re-emerging disease. 89±94 (2003). Trop. 73. 301±305 (2004). Analysis on the epidemiologic features of Dengue fever in Guangdong province. Public Health 23. The timeliness of notification of clinically suspected cases of dengue imported into north Queensland. Sather GE. 15. including molecular-based. A focal. He J. ]"Emerging infectious diseases": denguefever. The new standardized diagnostic tool kits. 3. Zheng K. 133±151 (2003). Mas E. Epidemiol. Health issues of air travel. 17. (Barc. Health 6. Further development of new efficient and inexpensive diagnostic tool kits will be useful. North Queensland. (Berlin) 45. Sante 13. Imported dengue in French university hospitals: a 6-year survey. Kamil M. In treatment. 755±759 (1995). nanodiagnostic and point-of-care testing tool kits will be useful in diagnosis of infection. Trop. Intell. Am. 10. 50. Stark K. Baisley KJ. Infectio-Sud Group. 1280±1284 (1986). Kuno G. Deshpande GC. Burger R. 11. The ongoing research on antiviral drugs might be the clue to better treatment. presumptive clinical diagnosis of dengue is. Five-year View Within the next 5 years. Epidemiological and ecological characteristics of past dengue virus infection in Santa Clara. 414±417 (1999). 223±224 (2000). Arboviruses associated with human disease in Australia. Reiskind MH. Pinheiro FP. Fabiyi A. 12. 684±692 (2004). DeHart RL. J. at present. J. Monath TP. Wilson ML. Giner V. Trans. J. Foley PN. Parra JP. 13. 50. 8.] Internist. Dis. 152. 4. New antiviral drugs will become available and aid in the management of dengue infection in the next 5 years. Int. Cope SE. Zhonghua Liu Xing Bing Xue Za Zhi 21. Commun. Gascon J. 427±430 (2002). Hyg. Geographic changes in exposure to dengue. Li L. supportive and symptomatic treatment is the key practice. Krause G. West-Nile-fever. Q.Expert Commentary It is important to know how to diagnose and treat dengue infection in tropical medicine. Sharp TW. Menard B. Calampa C. Zhoa Z. still useful. World Health Organ. Russell RC. Trop. SARS. World Health Stat. Ammon A. Med. Badiaga S. 10. Peru. Fagbami AH. Med. 596±600 (2001). 583±586 (1998). 14. Hyg. avian influenza. Haas W. Gubler DJ. Zhonghua Liu Xing Bing Xue Za Zhi 23. Luo H. Trop. Rodier GR. Soc. Barrau K.

‡ Summary on laboratory diagnosis for dengue. Appl. 23. Southeast Asian J. Global situation of dengue and dengue haemorrhagic fever. Detection of dengue HI and IgM antibody: is it diagnostically useful? When and how? J. Health 7. 127±128 (2005). Quatresous I. Virol. Wiwanitkit V. 38. Exot. Dengue: an update. 20. 113±117 (2002). Falconar AK.): importance of its bioecology in the transmission of dengue and other arboviruses. 50. Int. Doct. and 3. Guzman MG. 28. 26. Methods 163. Ngo TN. Infect. 36. Virol. A study on functional similarity between dengue non structural protein 1 and platelet integrin/adhesin protein. Barboza P. Wiwanitkit V. Degallier N. Conceição TM. Dis. Wiwanitkit V. Wiwanitkit V. 10.18. CD61. 13±16 (2006). Public Health 18. The tourniquet test is still a good screening tool for dengue illness. 179±184 (2004). 112 (2005). Clin. da Fonseca BA. World Health Stat. Corber SJ. Sa GC. Schilling S. 22. Dis. 31. 897±916 (1997). 18. Wills B et al. Rev. 8. Bleeding and other presentations in Thai patients with dengue infection. Teles FR. Dengue virus infections. Trop. Van An L. Virol. 33±42 (2002). Lopes da Fonseca BA. Dengue virus nonstructural-1 protein (NS1) generates antibodies to common epitopes on human blood clotting. 2 (2004). Trends in dengue diagnosis. 34. Tarantola A. Q. Fonseca SN. 27. Paquet C. Curr. J. Thammaborvorn R. 1). De Paula SO. 287±302 (2005). Infect. I Bull. J. J. 239±240 (2005). Dengue virus nonstructural-1 protein and its phylogenetic correlation to human fibrinogen and thrombocytes: a study to explain hemorrhagic complication. Patarapotikul J. Med. 38. Dengue: a review of the laboratory tests a clinician must know to achieve a correct diagnosis. Thromb. De Paula SO.Nanomedicine 1.J. 407±412 (1987). 27. 1±9 (2010). Travassos da Rosa AP. Virol. . 40. Kouri G. an explanation for the immune mimickingtheory in pathophysiologic findings in the recovery phase of dengue. 25. Wiwanitkit V. 9. 1060 (2005). and their quantitation in clinical and laboratory samples. 24. 67±71 (2002). Guzman MG. Hemost. Emerging viral infections in South East Asia and the Pacific region. Int. 125±132 (2002). 15. 254±257 (1995). 35. J. J. Proteomics 1. Med. Wang S. 35. Lima-Filho JL. Soc. Laboratory diagnosis of primary and secondary dengue infection. Lung Dis. A real-time PCR procedure for detection of dengue virus serotypes 1. Thai 84(Suppl. Med. 142. Pediatr. Dengue and dengue hemorrhagic fever in the Americas: lessons and challenges. Anderson R. Bleeding problem in dengue haemorrhagic fever: platelets and coagulation changes. buffy-coat and serum as clinical samples. 31. Weak binding affinity of immunoglobin G. Schmitz H. Virol. Lancet Infect. Trop. 21. 97±110 (1988). 39. 19. Fonseca BA. Thromb. J. 14. Pinheiro FP. Bhattarakosol P. Platelet CD61 might have an important role in causing hemorrhagic complication in dengue infection. Evaluation of the World Health Organization standard tourniquet test and a modified tourniquet test in the diagnosis of dengue infection in Vietnam. Virol. Wiwanitkit V. Trop. 37. 2. Da Poian AT. Ayub. Paediatric Hospital Study Group. Herve JP. Hemost. Aedes aegypti (L. Virology 213. 29. Clin. Abbottabad. S148± S154 (2001). ‡ Summary on laboratory diagnosis for dengue. Tuberc. Pathol. Arch. Kowitdamrong E. and its emergence in the Americas. He R. Antibody-enhanced binding of dengue-2 virus to human platelets. Ludolfs D. 2. Med. Assoc. 513±523 (2008). Wiwanitkit V.Clin. Sorgine MH. 1±13 (2003). Braz. Filiales 81. Kouri G. Mungmee V. Med. Coll. Mollet T. 11. Mitrakul C. Innis BL. integrin/adhesin proteins and binds to human endothelial cells: potential implications in haemorrhagic fever pathogenesis. Genom. 397±398 (2004). Optimizing dengue diagnosis by RT -PCR in IgM-positive samples: comparison of whole blood. Cao X T. Prazeres DM. 30. Methods 102. Appl. Clin. 161±169 (1997). J. Semboonlor L. 390±398 (2004). Opin. Lassel L. Mal. Magnitude and pattern of pulmonary pathology in fatal cases of dengue hemorrhagic fever in Thailand. 33. Med. 32. Int.

Website 101. Garin D.41. 4. 48. 25. advances and challenges. Dengue diagnosis. Infect. Lee YF. treatment. ‡ Commentary on future of laboratory diagnosis for dengue. Yang HH. An integrated microfluidic system for rapid diagnosis of dengue virus infection. Cao XT. 745±752 (2009). Bessaud M. Current and future directions in the technology relating to bedside testing of critically ill patients. Virol. Pastorino B. 43. Clin. 1.). 46. S204±S214 (1990). Aided Mol. Nanomedicine: diagnosis to therapy. Peyrefitte CN. Clin.who. Tai DF. Rothman RE. Sci. Lee WC. 337±348 (2004). Med. Wiwanitkit V. Schul W et al. Chen LK. Matulewicz MC. J. Peng KC. Bioelectron. 73±79 (2003). Lee GB. Dis. Crance JM. Design. 204±213 (2001). 68. 51. 1051± 1055 (2001). Kneen R et al. 15549±15554 (2009). 8. Li Q. 6 ±azauridine and glycyrrhizin: antiviral compounds active against pathogenic flaviviruses. Chen YL. Frecer V. Huang JH. Integrated reverse transcription polymerase chain reaction systems for virus detection. Yang S. and future applications in acute-care settings. Natl Acad. Damonte EB. Collison M. Management of dengue fever in ICU. 2399±2419 (2004). Med. Dis. Med. Evidence for in vitro falsely-primed cDNAs that prevent specific detection of virus negative strand RNAs in dengue-infected cells: improvement by tagged RT-PCR. Biosens. 54. Acute management of dengue shock syndrome: a randomized double blind comparison of 4 intravenous fluid regimens in the first hour. Ngo NT. 53. Craighead HG. 553±560 (2001). Lei HY. 49. Trop. ‡ Commentary on future of laboratory diagnosis for dengue. Chem. ‡ Details usefulness of nanotechnology for diagnosis of infection. A method for nanofluidic device prototyping using elastomeric collapse. Gupta D. Antiviral Res. J. Lee GB. J. Jouan A. Shyu RH et al. Scaramozzino N. Che P. Bioelectron. 50. Pediatr. 58. Exp. Wang L. USA 106. ribavirin. Cerezo AS. Huh YS. WHO. 69±80 (2004). Biosens. Des. Lei HY. J. Lancet Infect. Towards the design of antiviral inhibitors against flaviviruses: the case for the multifunctional NS3 protein from dengue virus as a target. Couissinier-Paris P. Indian J. 56. 80. 42. Soni A. Dis. An adenosine nucleoside inhibitor of dengue virus. J.pdf Papers ‡ of interest of special note have been highlighted as: . 22. optimization and validation of an assay for high throughput antiviral drug screening against dengue virus. limitations. Lien KY. 52. Chest 97(5 Suppl. 55. Comput. 94±101 (2008). Tolou HJ. Bioelectron. Meyerhoff ME. Huang JL. PCR-based diagnostics for infectious diseases: uses. 20435±20439 (2009). J. 58. Erickson D. 11. Xu T et al. Misiano DR. Guzmán MG. Virol. The development. 19±28 (2003).32. 8. Luo D. 57. Biosens. Sulfated seaweed polysaccharides as antiviral agents.int/publications/2009/9789241547871_eng. Dengue ± guidelines for diagnosis. Curr. 65. Lien KY. Int. Proc. 1739±1748 (2007). Interferon. 689±695 (2005). Piezoelectric immunochip for the detection of dengue fever in viremia phase. 47. Proc. Lescar J. USA 106. High-level expression of recombinant dengue viral NS-1 protein and its potential use as a diagnostic antigen. Miertus S. Int. ‡ Details on management of a dengue case. Yin Z. Infect. Sachdev A. Park SM. Sci. Wu TZ. Chugh K. Asian Pac. 68±70 (2008). 2009 http://whqlibdoc. Antiviral Res. Kourí G. 24(3). 363±373 (2009). 44. 195± 212 (2010). prevention and control ± new edition. Natl Acad. 45. structure-based focusing and in silico screening of combinatorial library of peptidomimetic inhibitors of dengue virus NS2B-NS3 protease. Su CC. Med. Methods 113. 15.

Sign up to vote on this title
UsefulNot useful